Up­dat­ed: FDA ad­comm votes to lim­it Op­di­vo, Keytru­da use in stom­ach, esophageal can­cers based on key bio­mark­er

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee on Thurs­day vot­ed 10-2 with one ab­sten­tion that Mer­ck’s Keytru­da and Bris­tol My­ers Squibb’s Op­di­vo are not ben­e­fi­cial as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER